Michael S Gordon (Michael Gordon)

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 3

Top Topics

Renal Cell Carcinoma

Ejection Fraction

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

Investigational new drugs

HonorHealth Research Institute

This page only lists publications with an associated author ORCID identifier.

Affiliation History

HonorHealth Research Institute Apr 01 2016

United States

Medical Director

Publications

Tae Won Kim, Howard A Burris, Maria J de Miguel Luken, Michael J Pishvaian, Yung-Jue Bang, Michael S Gordon, Ahmad Awada, D Ross Camidge, F Stephen Hodi, Grant A McArthur, Wilson H Miller, Andres Cervantes, Laura Q M Chow, Alexander M Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang-Chiung Chen, Eric G Stefanich, Tony Pourmohamad, Maria Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L Siu
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (16) (2022)
Michael S Gordon, John J Nemunaitis, Minal Barve, Zev A Wainberg, Erika P Hamilton, Ramesh K Ramanathan, George W Sledge, Huibin Yue, Susan E Morgan-Lappe, Martha Blaney, Sreeneeranj Kasichayanula, Monica Motwani, Lan Wang, Louie Naumovski, John H Strickler
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Molecular cancer therapeutics 20 (10) (2021)
Bradley Alexander McGregor, Michael S Gordon, Ronan Flippot, Archana M Agarwal, Saby George, David I Quinn, Mark Rogalski, Thomas Hawthorne, Tibor Keler, Toni K Choueiri
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Investigational new drugs 38 (6) (2020)